However, due to the significant association between SNAP‐25 and p‐tau proteins, the clinical utility of SNAP‐25 as a diagnostic biomarker for AD may be limited, while SNAP‐25 may be useful for monitoring disease progression or treatment response. The gene discussed is MAPT; the disease is Alzheimer disease.